References
- Ozdek S, Bahceci UA, Gurelik G, Hasanreisoglu B. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema. J Diabetes Complications. 2006;20(4):246–51. doi:10.1016/j.jdiacomp.2005.06.015.
- Ozdek S, Deren YT, Gurelik G, Hasanreisoglu B. Posterior subtenon triamcinolone, intravitreal triamcinolone and grid laser photocoagulation for the treatment of macular edema in branch retinal vein occlusion. Ophthalmic Res. 2008;40(1):26–31. doi:10.1159/000111155.
- Ozkiris A. Intravitreal triamcinolone acetonide injection for the treatment of posterior uveitis. Ocul Immunol Inflamm. 2006;14(4):233–38. doi:10.1080/09273940600826604.
- Tsai MJ, Yang CM, Hsieh YT. Posterior subtenon injection of triamcinolone acetonide for pseudophakic cystoid macular oedema. Acta Ophthalmol. 2018;96(7):e891–e893. doi:10.1111/aos.13200.
- Hirano Y, Ito T, Nozaki M, Yasukawa T, Sakurai E, Yoshida M, Ogura Y. Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes. Jpn J Ophthalmol. 2009;53(5):519–22. doi:10.1007/s10384-009-0692-5.
- Hirooka K, Shiraga F, Tanaka S, Baba T, Mandai H. Risk factors for elevated intraocular pressure after trans-tenon retrobulbar injections of triamcinolone. Jpn J Ophthalmol. 2006;50(3):235–38. doi:10.1007/s10384-005-0306-9.
- Hsieh YT, Yang CM, Chang SH. Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. J Formos Med Assoc. 2017;116(8):599–605. doi:10.1016/j.jfma.2016.09.014.
- Iwao K, Inatani M, Kawaji T, Koga T, Mawatari Y, Tanihara H. Frequency and risk factors for intraocular pressure elevation after posterior sub-Tenon capsule triamcinolone acetonide injection. J Glaucoma. 2007;16(2):251–56. doi:10.1097/IJG.0b013e31802d696f.
- Kawamura R, Inoue M, Shinoda H, Shinoda K, Itoh Y, Ishida S, Tsubota K. Incidence of increased intraocular pressure after subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther. 2011;27(3):299–304. doi:10.1089/jop.2010.0184.
- Yamamoto Y, Komatsu T, Koura Y, Nishino K, Fukushima A, Ueno H. Intraocular pressure elevation after intravitreal or posterior sub-Tenon triamcinolone acetonide injection. Can J Ophthalmol. 2008;43(1):42–47. doi:10.3129/i07-186.
- Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. Drugs Aging. 1999;15(6):439–50. doi:10.2165/00002512-199915060-00004.
- Clark AF, Wordinger RJ. The role of steroids in outflow resistance. Exp Eye Res. 2009;88(4):752–59. doi:10.1016/j.exer.2008.10.004.
- Chan LW, Hsu WC, Hsieh YT. Subtenon triamcinolone acetonide removal for uncontrolled ocular hypertension after posterior subtenon injection of triamcinolone acetonide. J Glaucoma. 2016;25:e268–272.
- Chawan-Saad J, Wu M, Wu A, Wu L. Corticosteroids for diabetic macular Edema. Taiwan J Ophthalmol. 2019;9(4):233–42. doi:10.4103/tjo.tjo_68_19.
- Sacconi R, Giuffre C, Corbelli E, Borrelli E, Querques G, Bandello F. Emerging therapies in the management of macular edema: a review. F1000Res. 2019. doi:10.12688/f1000research.19198.1.
- Otsuka H, Kawano H, Sonoda S, Nakamura M, Sakamoto T. Particle-induced endophthalmitis: possible mechanisms of sterile endophthalmitis after intravitreal triamcinolone. Invest Ophthalmol Vis Sci. 2013;54(3):1758–66. doi:10.1167/iovs.12-11247.
- Agrawal S, Agrawal J, Agrawal TP. Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 2004;138(4):679–80. doi:10.1016/j.ajo.2004.05.031.